SCHEMBL2166903

SCHEMBL2166903

CC(=O)c1ccn2nccc(Oc3ccc(NC(=O)c4c(C)n(C)n(-c5ccc(F)cc5)c4=O)cc3F)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 17/20 0.61
AXL P30530 11/20 0.61
MERTK Q12866 2/20 0.61
FLT3 P36888 1/20 0.61
TYRO3 Q06418 1/20 0.61
KDR P35968 9/20 0.57
IGF1R P08069 5/20 0.57
AURKA O14965 1/20 0.57
JAK2 O60674 1/20 0.57
RPS6KA5 O75582 1/20 0.57
ABL1 P00519 1/20 0.57
INSR P06213 1/20 0.57
LCK P06239 1/20 0.57
RET P07949 1/20 0.57
KIT P10721 1/20 0.57
PIM1 P11309 1/20 0.57
FGFR1 P11362 1/20 0.57
SRC P12931 1/20 0.57
PRKACA P17612 1/20 0.57
RPS6KB1 P23443 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963142 0.95 MET (0.64) METAXLMERTKFLT3TYRO3
SCHEMBL1963452 0.92 MET (0.61) METAXLMERTKFLT3TYRO3
SCHEMBL1967899 0.91 MET (0.61) METAXLMERTKFLT3TYRO3
SCHEMBL1965365 0.91 MET (0.61) METAXLMERTKFLT3TYRO3
SCHEMBL1963566 0.89 MET (0.59) METAXLMERTKFLT3TYRO3
SCHEMBL1963764 0.89 MET (0.70) METAXLMERTKFLT3TYRO3
SCHEMBL12473527 0.89 MET (0.55) METAXLMERTKFLT3TYRO3
SCHEMBL1966613 0.88 MET (0.64) METAXLMERTKFLT3TYRO3
SCHEMBL1966517 0.87 MET (0.66) METAXLMERTKFLT3TYRO3
SCHEMBL12473522 0.87 MET (0.62) METAXLMERTKFLT3TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289509-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR NEOPHARM CO., LTD. (KR) 2012-11-15 US claimed
US-20110183983-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR NEOPHARM CO., LTD. (KR) 2011-07-28 US claimed
US-8957102-B2 Heterocyclic compound as protein kinase inhibitor NEOPHARM CO., LTD. (KR) 2015-02-17 US disclosed
US-8957102-B2 Heterocyclic compound as protein kinase inhibitor NEOPHARM CO., LTD. (KR) 2015-02-17 US disclosed
US-20120289509-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR NEOPHARM CO., LTD. (KR) 2012-11-15 US disclosed
US-20120289509-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR NEOPHARM CO., LTD. (KR) 2012-11-15 US disclosed
US-20110183983-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR NEOPHARM CO., LTD. (KR) 2011-07-28 US disclosed
US-20110183983-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR NEOPHARM CO., LTD. (KR) 2011-07-28 US disclosed
WO-2010044543-A2 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR 주식회사 네오팜 (KR) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183983-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR MET, HGFAC, DMPK MET 1/4885AXL 234/4885MERTK 23/4885
US-20120289509-A1 HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR MET, HGFAC, DMPK MET 1/4885AXL 234/4885MERTK 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.